Zoster Vaccine Recombinant, Adjuvanted

BIOLOGICAL2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Wuhan BravoVax Co., Ltd.

Conditions

Chronic Lymphocytic Leukemia (CLL)Compare SHINGRIX Vaccine Response RatesHerpes ZosterSafety and TolerabilitySmall Lymphocytic Lymphoma (SLL)

Phase 1

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Wuhan BravoVax Co., Ltd.Herpes Zoster

Start: 2023-08-01End: 2024-07-31Target: 40Updated: 2023-02-08

Phase 2

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

CompletedNCT03702231

National Heart, Lung, and Blood Institute (NHLBI)Chronic Lymphocytic Leukemia (CLL), Compare SHINGRIX Vaccine Response Rates, Safety and Tolerability +1

Start: 2018-12-07End: 2023-07-12Updated: 2023-08-04

Related Papers

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL

Blood Advances2022-02-1423 citations

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Blood2021-11-05

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Blood2020-12-01134 citations

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Blood2019-11-139 citations